A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma

Trial Profile

A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2018

At a glance

  • Drugs MP 0250 (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Molecular Partners AG
  • Most Recent Events

    • 07 May 2018 According to a Molecular Partners media release, independent dose escalation committee recommended to continue the clinical study at the higher dose of 12mg/kg and the first patient in the second dose cohort has been dosed recently.
    • 07 May 2018 According to a Molecular Partners media release, preliminary results (n=8) from the first dose cohort treated with 8 mg/kg of MP0250, were presented at the 1st European Myeloma Network Meeting.
    • 21 Apr 2018 According to a Molecular Partners media release, Dr. Hartmut Goldschmidt (Medical Clinic V, University clinic Heidelberg) is the primary investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top